TY  - JOUR
AU  - Díaz-Redondo, Tamara
AU  - Lavado-Valenzuela, Rocio
AU  - Jimenez, Begoña
AU  - Pascual, Tomas
AU  - Gálvez, Fernando
AU  - Falcón, Alejandro
AU  - Alamo, Maria Del Carmen
AU  - Morales, Cristina
AU  - Amerigo, Marta
AU  - Pascual, Javier
AU  - Sanchez-Muñoz, Alfonso
AU  - González-Guerrero, Macarena
AU  - Vicioso, Luis
AU  - Laborda, Aurora
AU  - Ortega, Maria Victoria
AU  - Perez, Lidia
AU  - Fernandez-Martinez, Aranzazu
AU  - Chic, Nuria
AU  - Jerez, Jose Manuel
AU  - Alvarez, Martina
AU  - Prat, Aleix
AU  - Ribelles, Nuria
AU  - Alba, Emilio
PY  - 2019
DO  - 10.3389/fonc.2019.01178
SN  - 2234-943X
UR  - https://hdl.handle.net/10668/27602
T2  - Frontiers in oncology
AB  - Background: Double blockade with pertuzumab and trastuzumab combined with chemotherapy is the standard neoadjuvant treatment for HER2-positive early breast cancer. Data derived from clinical trials indicates that the response rates differ among...
LA  - en
KW  - breast cancer
KW  - neoadjuvant
KW  - pertuzumab
KW  - real-world data
KW  - trastuzumab
TI  - Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data.
TY  - research article
VL  - 9
ER  -